Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Recruiting · NCT06059261 · Registry updated 2026-02-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2026-02-18 | NCT06059261 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chongqing University Cancer Hospital | 41 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | China | 54 |